Currently, limited therapeutic options are available in the clinic to treat MC-driven disorders.2 Most MC-stabilizing drugs and H1 antagonists have minimal activity against MCs, and many patients become refractory over time, underscoring the importance for new therapeutics.2 Anti-IgE monoclonal antibodies, e.g. omalizumab, have been shown to be effective in some allergic diseases, including chronic urticaria, eosinophilic asthma, and nasal polyposis. The gene discussed is IGHE; the disease is allergic disease.